Actavis is nearing a deal to acquire Allergan in a tie-up that would likely be the year’s largest and could help shield the Botox maker from hostile suitor Valeant.

Actavis on Monday said it would pay $66 billion in cash and stock for Allergan in a deal that appears to have thwarted a hostile takeover of the Botox maker. Deal, Valued at $66 Billion, Seen ...

A U.S. appeals court on Thursday upheld three Tris Pharma Inc patents covering a form of its ADHD drug Quillivant, rejecting a challenge from Teva Pharmaceuticals-owned generic drugmaker Actavis ...

Actavis stock rose 2% to 247.94. Allergan climbed 5% to 209. Allergan's board maintained all along that Valeant's offer "grossly undervalues" the company, which has achieved a strong IBD EPS Rank ...

Actavis said its new once-a-day Namenda XR has "significant advantages over twice-a-day Namenda that are particular meaningful for Alzheimer's patients and their caregivers." ...

Irish pharmaceutical company Actavis will buy Allergan, the maker of Botox, for $219 per share in cash and stock, the company said in a press release. Actavis' CEO Brent Saunders will lead the ...

Actavis will pay $26.04 plus 0.3306 share per Forest Labs share. That's equal to $92.65 as of Tuesday's close, following Actavis' 5% gain to 201.47. Forest Labs shot up 27.5% to 91.04.

So Actavis pivoted, announcing that they would be yanking Namenda IR from the market, forcing Alzheimer’s patients to switch to the new XR product, or forego their medication.

Commentary 'Actavis' and Reverse-Payments Suits in the Third Circuit After Five Years For over 20 years, purportedly anticompetitive patent-litigation settlement agreements between rival branded ...

Shares of specialty drugmaker Actavis have been hitting all-time highs lately. With an acquisition-fueled revenue bonanza taking place, is it time to buy shares of this red-hot biopharma?